Market Research Blog

The portable oxygen concentrators market is projected to reflect a highly promising 7.8% CAGR between the years of forecast from 2016 to 2026. The coronavirus outbreak is characterized by major respiratory symptoms owing to potentially low levels of oxygen in the patient’s body. Oxygen therapy is a crucial aspect of Covid-19 treatments, which is expected to strongly support the demand for portable oxygen concentrators throughout the crisis period.

“Portable oxygen concentrators are easy to carry and a number of variants are also approved for applications in airplanes. Coupled with the growing geriatric population and incidences of respiratory disease, the demand for portable oxygen concentrators is likely to continue growing in years to come,” states the FMI analyst.

Portable Oxygen Concentrators Market- Critical Takeaways

• Pulse flow technologies in portable oxygen concentrators are witnessing increasing demand owing to superior efficacy in treating COPD and other breathing problems.
• Home setting applications are contributing significantly to revenue, supported by owing to the trend of miniaturization and easy application of oxygen therapies.
• North America remains a leading market for portable oxygen concentrators owing to favorable government initiatives and a vast and widespread geriatric population.

Portable Oxygen Concentrators Market- Drivers

• Rising incidences of respiratory ailments such as COPD around the world supports market growth.
• Government spending on healthcare infrastructure and geriatric care provides lucrative opportunities.

Portable Oxygen Concentrators Market- Restraints

• Strict regulations associated with approval and use of portable oxygen concentrators hinder market growth.
• Prohibitory costs of portable oxygen concentrators, and lack of awareness in rural areas restrain adoption rates.

Coronavirus Impact on Portable Oxygen Concentrators Market

With the rapid spread of the coronavirus pandemic, the demand for essential medical equipment has shot up. The potentially severe respiratory symptoms, from poor oxygen levels in the patient’s bloodstream will bolster the demand for portable oxygen concentrators. Effective applications in home and hospital settings will contribute to adoption rates and revenue. Manufacturers will remain largely concerned with efforts to optimize supply and distribution channels to circumvent potential challenges from lockdown measures imposed in multiple countries.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-1061

Competitive Landscape

GCE Group, Koninklijke Philips N.V., O2 Concepts LLC, Inogen Inc., Foshan Keyhub Electronic Industries Co. Ltd., Chart Industries Inc., Oxus America Inc., Resmed Inc., Besco Medical Co., Invacare Corp., Precision Medical Inc., and Drive DeVilbiss Healthcare are some of the leading players in the portable oxygen concentrators market.

Manufacturers in the portable oxygen concentrators market are largely displaying interest in the development and launch of new products to boost functionality and widen their portfolios.

For instance, CAIRE Inc. has unveiled a next generation Freestyle Comfort portable oxygen concentrator with proprietary, self-adjusting functionality. OxygenToGo LLC has entered into a deal to provide Virgin Atlantic with portable oxygen concentrators for use in aircrafts. Similarly, ResMed has unveiled Mobi, a portable oxygen concentrator for COPD patients in the United States.

Key Segments:

By Product

• Continuous Flow Portable Oxygen Concentrator
• Pulse Flow Portable Oxygen Concentrator

By End User

• Hospitals
• Homecare
• Ambulatory  Surgical Centres
• Travel Agents

By Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• APEJ
• MEA
• Japan

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-1061

Table of Content

1. Assumptions and Acronyms Used
2. Research Methodology
3. Executive Summary
4. Portable Oxygen Concentrators Market Overview

4.1. Introduction

4.1.1. Portable Oxygen Concentrators Market Definition

4.1.2. Portable Oxygen Concentrators Market Taxonomy

4.2. Portable Oxygen Concentrators Market Snapshot

4.3. Portable Oxygen Concentrators Market Scenario Forecast

5. Portable Oxygen Concentrators Market Forecast

5.1. Portable Oxygen Concentrators Market Value Forecast

5.2. Portable Oxygen Concentrators Market Volume Analysis

5.3. Regional Average Pricing Analysis (2015)

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-1061

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

According to a recent study by Future Market Insights (FMI), the global protein A resins market is expected to witness high growth during the forecast period. The market is expected to grow from US$ 536.6 Mn in 2020 to over US$ 1.2 Bn by 2031. This reflects a cumulative CAGR of around 8.1% over the forecast period (2021-2031).

Increasing researches conducted on monoclonal antibodies are driving demand for protein A resin. Since the commercialization of the first therapeutic monoclonal antibody in 1986, till May 2021, around 100 monoclonal antibody products have been approved by the U.S. FDA and European Medical Agency for the treatment of various diseases such as cancer.

Monoclonal antibody therapy for the treatment of mild to moderate COVID-19 in patients has also been approved by the FDA under Emergency Use Authorization (EUA).

Studies on monoclonal antibodies have indicated that more monoclonal antibody therapies are in the process of getting FDA approval and can be marketed in the near future to cater to rising demand in the global life sciences industry. Thus, increasing research on monoclonal antibodies (mAb) is expected to fuel the demand and utilization of protein A resin for purification and precipitation purposes.

For the purification of monoclonal antibodies (mAb), different technologies are available which includes membrane chromatography, mixed chromatography, and aqueous two-phase extractions (ATPS). However, protein A resin holds the top position for the purification of mAbs.

With many industries facing issues of leaching of ligand and resistance during the commercialization of monoclonal antibodies (mAbs), the availability of next-generation protein A resins with improved purification conditions, such as alkaline-stability, and with very low ligand leaching, is expected to increase the production and throughput demand for protein therapeutic processes.

Furthermore, in June 2018, Purolite Life Sciences launched a novel next-generation Protein A agarose resin, Praesto Jetted A50. GE Healthcare, in 2017, introduced a next-generation protein A resin, MabSelect PrismaA, which was designed to enable biopharma manufacturers to improve their mAb purification capacity by up to 40% over GE Healthcare’s existing protein A affinity medium. These product launches are expected give tailwinds to growth registered in the market.

Such developments not only strengthen the company’s existing portfolio but also help to increase their presence at the regional as well as global level.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-1720

Key Takeaways from Protein A Resin Study

• By product, the natural protein A resin hold the maximum share of 62.8% in 2021. Natural protein A is derived from a bacterial cell of the staphylococcus aureus species and mainly used in the purification of monoclonal antibodies.
• By matrix, the agarose based matrix of protein A resin account for 85.8% of the market share in 2021 indicating the highest demand, offering high binding specificity when in comparison to other matrices and are widely used for the attachment of ligands that bind proteins.
• By application, the antibody purification of protein A resin segment will account for 74.8% of the market share in 2021.
• By end user, the biopharmaceutical manufacturers will account for 79.2% of the market share in 2021.
• By region, North America held the largest share of 35.7% of the global protein A resins market in 2021.
• The U.S. will emerge as a leading market in North America, while growth registered in Europe will be spearheaded by Germany and the U.K.

“Increasing demand of protein A Resins for biologics production including monoclonal antibody and biosimilars is expected to drive the demand of protein a resin over the decade. To capitalize on existing opportunities, market players are expected to push investment towards product launches and research initiatives,” says the FMI Analyst

Who is Winning?Some of the leading manufacturers of protein A resin market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence.

• In August 2021, Danaher Corporation acquired Aldevron and stated that Aldevron will work as a stand-alone operating firm and brand within the life sciences segment of Danaher to provide a vast range of custom biologic services, including plasmid DNA production, mRNA production, and antibody development.
• On 11 February 2021, Thermo Fisher Scientific Inc. started the online offering of its essential Thermo Scientific Dionex Easion and Thermo Scientific Dionex Aquion Ion Chromatography (IC) systems through easy online ordering.  This step was undertaken in order to reduce the in-person transaction during the pandemic.
• In October 2020, Kaneka Corporation collaborated with the biomedical research institute “de Duve Institute” of the University of Louvain, wherein they signed a research collaboration agreement in order to develop innovative biomedicine production technologies and strengthen and expand the company’s current biomedicine CDMO business.
• In April 2020, Bio-Rad Laboratories, Inc. launched a blood-based immunoassay kit to identify antibodies to the coronavirus SARS-CoV-2, the virus associated with COVID-19.

The key market players covered by FMI include :

• GE Healthcare
• Thermo Fisher Scientific
• Kaneka Corporation
• JNC Corporation
• Purolite Life Sciences
• Bio-Rad Laboratories Inc.
• JSR Corporation (JSR Life Sciences LLC)
• Repligen
• Tosoh Bioscience
• Merck Group (Merck Millipore)
• Novasep Holdings SAS
• Agilent Technologies Inc.
• GenScript
• Abcam PLC (Expedeon Ltd.)
• Avantor Inc.
• Takara Bio
• PerkinElmer Inc.
• Suzhou Nanomicro Technology Co. Ltd.

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-1720

Key Segments:

Product:

• Natural Protein A Resin
• Recombinant Protein A Resin

Matrix:

• Agarose Based Matrix
• Glass or Silica Based Matrix
• Organic Polymer Based Matrix

Application:

• Immunoprecipitation
• Antibody Purification

End User:

• Biopharmaceutical Manufacturers
• Clinical Research Laboratories
• Academic Institutes

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-1720

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

ESOMAR-certified consulting firm Future Market Insight (FMI) presents incisive global automated suturing devices market survey for the forecast period of 2021-2031. According to the report, the market is expected to expand, rising at a CAGR of 7.3 % during the forecast period.

Surgical suture devices find application in laparoscopy, orthopedic surgery, cardiovascular surgery, gynecology, orthopedic, and ophthalmology as they are majorly used for treating wounds and injuries.

Rising cases of surgeries due to increasing accidents and trauma cases are boosting demand for automated suturing devices in the global market. According to the Ministry of Road Transport and Highways, India, in 2018, the nation was leading in road accident deaths followed by United States and China.

According to the World Health Organization’s (WHO’s), Global Report on Road Safety 2018, India accounted for 11% accident related deaths in the world. A total of 4,67,044 road accidents, 51,417 deaths, and 4,69,418 injuries. The rise in number of accidents and the increasing need for surgeries will propel the need for automated suturing devices, thereby augmenting the growth of the market.

Automated suturing devices are preferred over conventional suturing as they aid in delivering better wound healing and lowers post-surgery duration of hospital stay. That’s why it is extensively used for open and minimally invasive surgeries.

Key Takeaways from FMI’s Automated Suturing Devices Market Study

• The automated suturing devices market in the U.S. will witness positive growth owing to rising prevalence of cardiovascular diseases and requirement for invasive procedures in the country.
• France will find lucrative opportunities during the forecast period as according to the Organization of Economic Cooperation and Development, approximately 148075 minimal invasive surgeries took place in France in 2018. The country also has presence of several manufacturers such as Guerbet, Sanofi, and others.
• Disposable automated suturing devices are expected to lead the product segment as they are cost-effective. Rising demand for laparoscopy and minimally invasive procedures are also encouraging demand for the same.
• Hospitals will exhibit high demand for automated suturing devices since they receive a higher footfall of patients on a daily basis.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-579

“Several leading players are aiming for clearance from the United States Food and Drug Administration to launch advanced automated suturing devices. With focus on technological improvements on cards, the market is expected to gain momentum in the coming years,” says a FMI analyst.

Who is Winning?

Key players in the global automated suturing devices market are focusing on adopting inorganic strategies such as alliance, collaboration, partnerships, and merger and acquisitions to strengthen their position in the supply chain channels.

They are also emphasizing on launching new products and expanding their product portfolio. Key players operating in the global automated suturing devices market are Medtronic Plc., Boston Scientific, C. R. Bard, Inc., Apollo Endosurgery, EndoEvolution, LLC, LSI Solutions, Inc., and SuturTek Inc.

On March 3^rd 2020, Origami Surgical launched StitchKit, a patented suture delivery and retrieval system. The U.S. Food and Drug Administration (FDA) approved 510k clearance for three novel types of sutures for the company’s StitchKit robotic surgery platform.

On November 2020, Healthium Medtech, one of India’s largest medical devices company, launched Trubarb, its latest innovation. This innovation is a knotless tissue closure device that reforms the suturing experience.

On June 1^st 2021, Anchora Medical, a Alon Medtech Venture’s company, announced closing of $4.5million financing led by HOYA Corporation and Tal Capital. The funds will be utilized for completing Anchora’s single use laparoscopic suturing devices.

Key Segments:

Product

• Reusable Automated Suturing Devices
• Disposable Automated Suturing Devices

Applications

• Minimally Invasive Surgeries
• Open Surgeries
• Trauma Cases

End Use

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Region

• North America (US and Canada)
• Latin America (Brazil, Mexico and Rest of Latin America)
• Western Europe (Germany, France, Spain, UK,)
• Eastern Europe (Bulgaria, Croatia, Russia, Czech Republic)
• Asia Pacific Excluding Japan (India, China, Vietnam, Australia and Others)
• Japan
• Middle East & Africa (GCC, South Africa, Turkey and Rest of MEA)

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-579

Table of Content

1. Executive Summary
2. Assumption & Acronyms Used
3. Research Methodology
4. Market Overview

4.1. Market Taxonomy

4.2. Introduction & Parent Market Overview

4.3. Wound Closure Devices Market Overview

4.4. Global Automated Suturing Devices Market Analysis

4.4.1. Introduction

4.4.1.1. Market Value (US$ Mn) & Y-o-Y Growth

4.4.1.2. Absolute $ Opportunity

5. Global Automated Suturing Devices Market Dynamics

5.1. Drivers

5.2. Restraints

5.3. Trends

5.4. Drivers and Restraints Impact Analysis

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-579

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

According to a recent study by Future Market Insights (FMI), the global Bioprocess Technology Market was valued at US$ 17.3 Bn in 2020 and is expected to register a CAGR of 15.2% during the forecast period (2021-2031). It is projected to generate a revenue of US$ 81.2 Bn by the end of 2031.

Technology has always been at the heart of biotech. The emergence of advanced computing technology such as machine learning and artificial intelligence has enabled companies to expand the scale of their research and improve efficiency in the manufacturing process—both of which reduce the time it takes for biotech firms to bring new products to market.

Increasing research and development spending on pharmaceutical products has improved the well-being of patients to a significant level. Today vaccines have proven to be one of the most effective ways to prevent children from infectious diseases. This is highly possible due to increased government spending on research & development in the life science stream.

For instance, in May 2020, AbSci Inc. closed USD 15.4 Mn in series D funding to accelerate the growth and scale of disruptive protein printing technology, by announcing an exclusive co-marketing partnership with KBI Biopharma.

There are currently more than 1,500 biomolecules undergoing clinical trials, which target more than 100 hundred types of diseases and success rate for biologics has so far been over twice that of small-molecule products.

Key Takeaways from Bioprocess Technology Market Study

• In 2021, the BIOTECH/BIOPHARMACEUTICAL COMPANIES segment is expected to dominate the global bioprocess technology market with a 44.0% market share, whereas, CDMO/contract research organization segment is expected to occupy over 40% of the market share.
• By product, the upstream segment dominated the global Bioprocess Technology Market with a 64.8% market share.
• Europe and East Asia dominated the global Bioprocess Technology Market occupying over 24.3% and 14.7% market share, respectively.

Who is winning?

Some of the leading companies of Bioprocess Technology Market are focusing on their extensive portfolio of single-use cell culture bioreactors, containers, strong distribution channels, and strategic selling to the leading biopharmaceutical manufacturing entities.

• Thermo Fisher Scientific Inc. is a multinational biotech company that develops, manufactures, and distributes products in the areas of healthcare & diagnostics, life sciences, pharmaceuticals, and others. In Sep 2020, Thermo Fisher Scientific Inc. announced the opening of its new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri.
• Sartorius AG is a leading provider of contract testing services to the global biotechnology and biopharmaceutical industries. In July 2020, Sartorius Stedim Biotech acquired a majority stake in CellGenix to strengthen its product portfolio for cell and gene therapies.
• Danaher Corporation designs manufacture and markets professional, medical, industrial, and commercial products and services. In March 2020 Danaher Corporation acquired the Biopharma business from General Electric’s Life Sciences division.

The key market players covered by FMI include Thermo Fisher Scientific Inc, Sartorius, Merck KGa, Danaher Corporation, Applikon Biotechnology B.V., Lonza AG, Bio-Rad Laboratories, Agilent technologies, Solida Biotech GmBH, and Waters Corporation.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-13890

Key Segments:

Product:

• Upstream Equipment
  • Cell culture development products
    • Cell line development products
    • Cell Lines
    • Media, Sera and other additives
    • Cell line development kits
• Lab-scale Bioreactors
  • Continuous Stirred Tank Bioreactors
  • Bubble Column Bioreactors
  • Airlift Bioreactors
  • Fluidized Bed Bioreactors
  • Packed Bed Bioreactors
  • Photo-Bioreactors
• Scale-up and production products
  • Cell culture media and feeds
  • BioProcess Containers & Fluid Transfer Solutions

1. Single-use
2. Reusable

• • BioReactors

1. Single-Use Bioprocess Equipment
2. Continuous Bioprocess Equipment
3. Real-Time Bioprocess Equipment

• • Harvest and collection

• • • Harvest and separation products
    • Centrifuges for bioprocessing
    • Storage & Transport Products
      v. Production Tanks and Drums
      v. Outer Support Containers
• Testing Products
  • Cell Counters & Viability Analysis Systems
  • Contamination & impurity testing products
• Probes and Accessories
• Downstream Equipment
  • Downstream purification
    • Chromatography Instruments
    • Chromatography Columns
    • Others (Resins and accessories)
  • Buffer preparation and supply
    • Reagents
    • mixing systems
• Process analytical testing
  • Host cell residual DNA quantitation
  • Protein quantitation
  • Microbial identification
  • Others
• Probes and Accessories

End-User:

• Biotech / Biopharmaceutical Companies
• CDMO / Contract Research Organization
• Research / Academic Institutes

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa (MEA)

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-13890

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusion and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Method Innovation / Development Trends

4. Key Inclusions

4.1. Porters Analysis

4.2. PESTLE Analysis

4.3. Product Adoption Analysis

4.4. Key Strategies of Key Manufacturers

4.5. Technology Assessment

4.6. Regulatory Scenario

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-13890

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

According to the recent Future Market Insights (FMI) report, the stereotactic planning software spending analysis market is estimated to be US$ 252.6 Mn in 2021, with a market CAGR of 4.6% during the forecast period (2021-2031).

Stereotactic planning software is an interactive software tool used in stereotactic planning applications of recording chamber placement and electrode trajectories. It combines basic trajectory planning to obtain arc settings with advanced planning capabilities that improve O.R. workflows, localization of functional areas, and deep brain stimulation (DBS). The high prevalence of neurological disorders and small cell lung cancer is expected to boost the demand in the stereotactic planning software market. For instance, Parkinson’s disease and other movement disorders are estimated to affect 2.75 million people in the United States. According to DALY’s, in the U.S., stroke accounts for 3.58 Mn people, Alzheimer’s disease for 2.55 Mn, and migraine for 2.4 Mn.

Furthermore, increasing investments in better treatment options involving precision and artificial intelligence in the software provide impetus to the market by increasing the overall adoption rate. Patients are inclined towards safer and better treatment facilities with minimal incision. Stereotactic planning software facilitates surgeons to plan stereotactic surgery efficiently.

However, the unprecedented impact of the ongoing covid-19 pandemic has created a significant impact on the stereotactic planning software market due to a shortage of inpatient footfalls in hospitals and other centers.

Preference now is being given to the treatment of COVID-19 patients, thus halting product launches for stereotactic planning. Also, this has led to the postponement of the enrolment of the new participants is such studies. Now, with the availability and commencement of the COVID-19 vaccination, the research activities expected to resume in the near future.

Key Takeaways from Stereotactic Planning Software Spending Analysis Market Study

• Integrated stereotactic planning solutions are expected to grow 2x by 2031 as compared to 2021 owing to ease of use and higher adoption rates.
• CT scans are projected to capture over 46% of the global market by 2031. This is attributed to inherent accuracy in identifying and localizing intracranial lesions.
• North America is the largest revenue-generating region for stereotactic planning software, with the U.S. accounting for over 79% of the regional market.
• The U.K. holds the lead in Europe, accounting for over 37% of the region through the end of 2031.
• East Asia is poised to grow at the highest CAGR of 5.3% during the forecast period with China accounting for over 62% of the market owing to the large subclinical patient pool of patients.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-6452

Growing cases of neurological disorders, small cell lung cancer, and prostate cancer, along with an increase in patient awareness and screening, favorable reimbursement scenarios, approvals, and grants for product development are factors influencing market growth. The implementation of artificial intelligence, the use of visual improvements in real-time are some of the upcoming trends that are expected to create growth opportunities for manufacturers through the assessment period,” says the FMI Analyst

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global Stereotactic Planning Software Spending Analysis is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on Stereotactic Planning Software Spending Analysis based on solution type (Stand-alone Stereotactic Planning Solution, Integrated Stereotactic Planning Solution, Services), imaging modality (CT Images, MR Images, Angiographic Images), and end-user (hospitals, ambulatory surgical centers, cancer research institutes) across seven major regions.

Who is Winning?

Some of the leading companies operating in the stereotactic planning software spending analysis market are focusing on collaborations and mergers and acquisitions for global expansion options with a focus on emerging economies. Thus, enhancing their market presence. For instance,

• In March 2021, RaySearch Laboratories AB (publ) announced a sales agent agreement with Canon Medical Systems USA, Inc., enabling RaySearch America’s salesforce to promote Canon Medical’s Aquilion Large Bore CT and Celesteion PET/CT products.
• In March 2021, Brainlab announced the acquisition of Mint Medical GmbH. The acquisition aims to improve the structured diagnosis, analysis, and treatment of cancer and other diseases to address the demands of modern medicine and personalized treatments.

The key market players covered by FMI include Brainlab, Inc., Renishaw Inc., Inomed Inc., RaySearch Americas, Inc., Mevis Informática Médica, FHC, Inc., Integra LifeSciences Corporation, Elekta Solutions AB, and SurgiFRONT Ltd.

Key Segments:

By Solution Type:

• Stand-alone Stereotactic Planning Solution
• Integrated Stereotactic Planning Solution
• Services
  • Consulting & Implementation
  • Training Services
  • On-demand Support Services

By Imaging Modality:

• CT Images
• MR Images
• Angiographic Images

By End User:

• Hospitals
• Ambulatory Surgical Centers
• Cancer Research Institutes

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-6452

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusion and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Method Innovation / Development Trends

4. Market Background

4.1. Macro-Economic Factors

4.1.1. Global Healthcare IT Spending Outlook

4.1.2. Per Capita Healthcare Expenditure Outlook

4.1.3. Treatment Planning software Market Overview

4.2. Forecast Factors – Relevance & Impact

4.2.1. Rising Incidence of Neurosurgical Procedures

4.2.2. Adoption of Stereotactic Planning Software

4.2.3. Spending Per Software (US$)

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Trends

4.3.4. Opportunity Analysis

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-6452

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The transradial closure devices market is growing with the increasing cases of cardio vascular diseases all over the world. A new study by Future Market Insights (FMI) has projected the market to rise at 6.8% CAGR between 2022 and 2030. According to the report, demand will rise consistently on the back of surging cases of cardiovascular ailments caused by stress, unhealthy lifestyle, and others factors.

According to World Health Organization (WHO), every year cardiovascular diseases cause an estimated 31% of death occurring worldwide. Also a 2016 Heat Disease and Stroke Statistics update by the American Heart Association stated that over 15 million people in the U.S. have coronary heart disease.

With no signs of the incidence slowing down, the demand for procedures such as angiography, angioplasty, percutaneous coronary intervention (PCI), and others will continue rising. Consequently, the demand for transradial closure devices is surging rapidly all over the world.

Radial access is highly efficient in providing faster mobility to patients due to smaller incision.  Furthermore, chances of infection at site is lower in radial access as compared to transfemoral access, which makes it highly preferred by diverse end users, starting from hospitals to specialized clinics.

The outbreak of COVID-19 pandemic is anticipated to impact the market negatively. The temporary period of lull could continue until the next year. However, the transradial closure devices market has high potential to grow further in the coming years.

FMI offers an exhaustive overview of the transradial closure devices market, its growth drivers, and restraints.

“Due to the rising cases of cardio vascular diseases, there has been increase in surgical and diagnostic procedures related to it. Transradial access (RA) being associated with less complications, is highly preferred by the various end users such as ambulatory surgical centers, hospitals, and others. In the coming years, the uptake of transradial closure devices will therefore rise especially since patients are increasingly willing to spend on procedures that ensure shorter hospital stays,” says an FMI analyst.

Some of the key takeaways from the report are highlighted below-

• Band or strap based transradial closure type devices are expected to lead in the market during the forecast period
• Disposable devices are anticipated to gain traction in terms of usage
• Application of transradial devices in diagnostic segment will remain high throughout the forecast period
• Among the end users, independent catheterization centres will emerge dominant in the coming years
• North America will lead in the global market followed by Europe

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-12841

COVID-19 Impact Analysis

Due to the outbreak of COVID-19 pandemic, manufacturing process of transradial closure devices was hampered during the lock down. Contrary to this, novel coronavirus might cause cardiovascular concerns, which has resulted in surge in demand for the transradial closure devices in hospitals, specialized clinics, and other segments.

As per the latest study by FMI, the global transradial closure devices market has high potential to overcome the threats posed by the ongoing pandemic and grow further in the coming years.

Who is Winning

The global transradial closure devices market is highly competitive. In order to strengthen their foothold market players are focusing on the launch of ultra-modern transradial closure devices.

For instance, Comed B.V has launched their new Io Radial Compression Tourniquet (IoRACT) which is effective to compress the radial artery puncture, post procedure in the current year. Their IoRACT is small, and especially designed to optimize compression, view the puncture side and deflate the compression balloon.

Merit Medical, Inc. has launched their exclusive PreludeSYNC Radial Compression Device which assists in achieving vascular hemostasis in the recent year. Their PreludeSYNC Radial Compression Device is available with the safety and convenience of a specialized connection device and syringe.

More Valuable Insights on Transradial Closure Devices Market

In the latest report by Future Market Insights, we offer an unbiased analysis of the global transradial closure devices market, providing historical data for the period of 2015-2019 and forecast statistics for the period of 2020-2030. In order to understand the global market potential, its growth and scopes, the market is segmented on the basis of product type (band/strap based, knob based, plate based), usage (disposable device, reusable device), application (surgical intervention, diagnostics), end user (hospitals, independent catheterization centers, ambulatory surgical centers, specialized clinics), across six major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA).

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-12841

Key Segments Of Transradial Closure Devices Industry Survey

Transradial Closure Devices Market by Product:

• Band/Strap-based Transradial Closure Devices
• Knob-based Transradial Closure Devices
• Plate-based Transradial Closure Devices

Transradial Closure Devices Market by Usage:

• Disposable Transradial Closure Devices
• Reusable Transradial Closure Devices

Transradial Closure Devices Market by Application:

• Surgical Intervention
• Diagnostics

Transradial Closure Devices Market by End User:

• Hospitals
• Independent Catheterization Centers
• Ambulatory Surgical Centers
• Specialized Clinics

Transradial Closure Devices Market by Region:

• North America Transradial Closure Devices Market
• Latin America Transradial Closure Devices Market
• Europe Transradial Closure Devices Market
• East Asia Transradial Closure Devices Market
• South Asia & Pacific Transradial Closure Devices Market
• Middle East & Africa (MEA) Transradial Closure Devices Market

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Transradial Closure Devices Adoption Rate/Usage Analysis- Key Statistics

4.2. Key Promotional Strategies, By Key Manufacturers

4.3. Key Regulations, By Region

Continued…!

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-12841

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

Increasing investments in the endometriosis treatment market by key stakeholders and rising awareness among women are the major factors expected to drive market growth. The global endometriosis treatment market was valued at US$ 2.8 Bn in 2018, and is expected to exhibit a CAGR of around 3% over the forecast period (2019-2030).

Rising prevalence of endometriosis condition has fueled the demand for endometriosis treatment across the world. High focus on the introduction of therapeutically-advanced endometriosis treatment options are expected to propel the growth of the market over the forecast period. Leading industry players are significantly accelerating the development of scientific and clinical therapeutic agents and new product launches in the global endometriosis treatment market. This considerable push by industry players is expected to drive future market growth.

Key Takeaways of Endometriosis Treatment Market Study

• Based on drug, oral contraceptives contributed maximum value share to the global endometriosis treatment market in 2018, owing to high preference for them as a first-line therapy for patients without contraindications, and efficacy in preventing recurrence of pelvic pain and endometriosis lesions.
• High treatment efficacy and acceptance with low risk are expected to result in notable share of hormonal therapy in the treatment type.
• The hospital pharmacies and retail pharmacies segments, collectively, hold above 60% of value share to the endometriosis treatment market, owing to the high patient pool in hospitals and visiting retail pharmacies.
• Europe captured a notable revenue share of 37% in 2018, and is expected to be the most lucrative region in the global endometriosis treatment market during the forecast period.
• Increasing government expenditure for high growth of the medical industry in emerging economies in the Asian region is expected to drive the growth of the endometriosis treatment market across this region.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-3870

Multiple New Indications – Imperative Strategy for Market Players

Increasing the introduction of endometriosis drugs with multiple new indications is a major factor responsible for intense competition among market players. Several companies are focusing on launching new endometriosis treatment options to increase their product sales and expand their market share. For example, in July 2018, AbbVie Inc. introduced a new innovative product – Orilissa™ (elagolix) tablets, a gonadotropin-releasing hormone (GnRH) receptor antagonist for the management of moderate to severe pain associated with endometriosis, in the U.S. market.

What else is in the report?

Future Market Insights (FMI) offers a unique perspective and actionable insights on the endometriosis treatment market in its latest study, presenting historical demand assessment of 2014-2018 and projections for the period of 2019-2030, based on drug (oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDs, and others), treatment type (hormonal therapy and pain management), and distribution channel (hospital pharmacies, retail pharmacies, drugstores, and e-Commerce), across seven key regions of the world.

Market segmentation

The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug:

• Oral Contraceptives
• Progestins
• NSAIDs
• GnRH Analogues
• LNR-IUDs
• Others

Treatment Type:

• Hormonal Therapy
• Pain Management

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drugstores
• e-Commerce

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-3870

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Drug Development Trends

4. Key Success Factors

4.1. Product Adoption / Usage Analysis

4.2. Endometriosis Epidemiology, By Key Region

4.3. Unmet Needs of Endometriosis Treatment

4.3.1. Potential Diagnostic Biomarkers for Endometriosis

4.3.1.1. Existing & Emerging Non-invasive Diagnostics Techniques

4.3.2. Disease Awareness and Educational Strategies for Medical Professionals

4.3.3. Drug Effectivity & Safety, By Drug

4.3.4. Marketed & Emerging Non-hormonal Therapies for Endometriosis

4.3.5. Disease Etiology and Pathophysiology

4.4. Research and Development Strategies

4.4.1. Reformulations and Label Expansion of Currently Marketed Drugs

4.4.2. Pipeline Assessment of GnRH Antagonists

4.4.3. Pipeline Assessment of Novel Non-hormonal Therapies

4.4.4. Key Strategies Followed By Manufacturers (Alliance, In-Licensing and Out-Licensing Strategies)

4.4.5. Strategy to Maximise Return on Investment (Drug Approvals for Secondary Indication)

4.5. Attributes/Factors Important in Clinical Trials

4.6. Clinical Trial History of Key Marketed Drugs

4.7. Attributes/Factors considered for Market Sizing of Historical Market Sizing & Opportunity Assessment of Pipeline Drugs

4.8. Pipeline Assessment/Clinical Benchmark Analysis

4.8.1. Marketed Drug/Pipeline Valuation Analysis

4.8.1.1. Therapeutic Advantages by Drug

4.8.1.2. New Drug Launches and Regulatory Approvals, 2019-2030

4.8.1.3. Opportunity Assessment in terms of Revenue, 2020-2025

4.8.1.4. Clinical Trials and Pipeline Overview

4.9. Regulatory Scenario

4.10. Reimbursement Scenario

4.11. Primary Verbatim, Key Opinion Leaders Opinion on Future Opportunities

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-3870

About Us    

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs